Voloridge Investment Management
BHVN

Voloridge Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Voloridge Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-97,175
Closed -$14.7M – 1709
2022
Q3 		$14.7M Sell
97,175
-32,744
-25% -$4.85M 0.08% 337
2022
Q2 		$18.9M Buy
129,919
+49,367
+61% +$6.31M 0.1% 280
2022
Q1 		$9.55M Sell
80,552
-41,394
-34% -$5.16M 0.05% 420
2021
Q4 		$16.8M Sell
121,946
-59,958
-33% -$7.62M 0.09% 307
2021
Q3 		$25.3M Buy
181,904
+170,177
+1,451% +$21.2M 0.16% 145
2021
Q2 		$1.14M Sell
11,727
-13,203
-53% -$1.07M 0.01% 1206
2021
Q1 		$1.7M Sell
24,930
-805
-3% -$65.1K 0.01% 868
2020
Q4 		$2.21M Sell
25,735
-41,261
-62% -$3.5M 0.02% 701
2020
Q3 		$4.36M Sell
66,996
-20,457
-23% -$1.34M 0.04% 482
2020
Q2 		$6.39M Buy
87,453
+79,053
+941% +$4.21M 0.07% 297
2020
Q1 		$286K Buy
+8,400
New +$384K 0.01% 887
2019
Q2 		– Sell
-12,964
Closed -$667K – 1257
2019
Q1 		$667K Buy
+12,964
New +$560K 0.02% 594

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Voloridge Investment Management's BHVN Position: Q4 2022 in Review

Voloridge Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 97,175 shares — an estimated $14.7M sold.

Voloridge Investment Management first reported a position in BHVN in Q1 2019 and held it in 12 quarters. The position peaked at $25.3M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Voloridge Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Voloridge Investment Management sold 97,175 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $14.7M.
  • Voloridge Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 12 quarters.
  • Voloridge Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $25.3M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Voloridge Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.